{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mastitis-breast-abscess/prescribing-information/flucloxacillin/","result":{"pageContext":{"chapter":{"id":"02c4d465-606a-5a45-bb76-7884e6655d29","slug":"flucloxacillin","fullItemName":"Flucloxacillin","depth":2,"htmlHeader":"<!-- begin field 0c531b4f-3270-4b1a-8a4b-a78200c4c9de --><h2>Flucloxacillin</h2><!-- end field 0c531b4f-3270-4b1a-8a4b-a78200c4c9de -->","summary":"","htmlStringContent":"<!-- begin item f2046f4c-649c-46c5-93ad-a78200c4c7cc --><!-- end item f2046f4c-649c-46c5-93ad-a78200c4c7cc -->","topic":{"id":"612445a9-31b6-5130-bb99-4389c0f9c4af","topicId":"8dd98aac-dd7a-4981-bb01-5e666b4686b6","topicName":"Mastitis and breast abscess","slug":"mastitis-breast-abscess","lastRevised":"January 2021","chapters":[{"id":"d054cbf1-e596-5afd-8a75-f3d051c621dc","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"de83cb42-8301-5164-81a9-f0c4ab5a83c2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"610b1eb8-dd62-5e7e-b3bf-deb28c7072aa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c44cbf7c-02c4-5674-abb6-1c6be6131e3b","slug":"changes","fullItemName":"Changes"},{"id":"9d333c13-3643-5811-9a29-a919983994aa","slug":"update","fullItemName":"Update"}]},{"id":"f993c606-c828-51da-a43a-6029a7e07f40","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4f11480-406f-5573-9e6b-b2747a513a11","slug":"goals","fullItemName":"Goals"},{"id":"5020b6cc-9441-50c0-b8dd-94fcf8bdf761","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"948e09e3-ff32-5344-a06f-e0a9331eff4f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e253dff2-3341-5c3a-8c2c-a8c5c9d27491","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7a7fe239-eefb-5a7a-936c-c1c01d919b6e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"844a01a3-e6d9-5962-905c-52aaa284973a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"13965c3c-cc8a-575f-8e2d-056c9590196a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"edd589e4-be3e-52d6-b1ea-c2095f08f38e","slug":"definition","fullItemName":"Definition"},{"id":"06b05f0c-3f18-5d1a-994a-02d388348b53","slug":"causes","fullItemName":"Causes"},{"id":"ac2b0ec4-d2dd-5b82-999f-aa4fb681433e","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"033ddd74-dfdc-5a2d-bb82-453baebee36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9ccd068b-aec1-59bb-a0dc-497e330227b3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"bf45f222-3e69-50c6-b73f-cd089ff22c65","slug":"complications","fullItemName":"Complications"}]},{"id":"1facde51-ce1f-55fa-889f-f079ac8b1283","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4d19871b-504c-5d1d-8e27-298e0a8e40b2","slug":"when-to-suspect-mastitis","fullItemName":"When to suspect mastitis"},{"id":"1a7eb0d1-33d6-539d-bfc3-0b12f1ec6451","slug":"when-to-suspect-a-breast-abscess","fullItemName":"When to suspect a breast abscess"},{"id":"3478864a-a09e-5e3f-ab1e-bd6dc34d0ae1","slug":"investigations","fullItemName":"Investigations"},{"id":"f70b7f79-5c5c-5a9d-a586-dad7ec33698c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1bdc74c8-e4f7-574c-a93a-ea9103718273","fullItemName":"Management","slug":"management","subChapters":[{"id":"7d9d079a-de35-5f76-8cfe-4303cce22c3e","slug":"management-lactating-women","fullItemName":"Scenario: Management - lactating women"},{"id":"95e2db4c-1f7a-5dfe-b04b-5edb440448bd","slug":"management-non-lactating-women","fullItemName":"Scenario: Management - non-lactating women"},{"id":"d1bd1c0d-5efe-5925-92a2-57663e0af1d5","slug":"management-breast-abscess","fullItemName":"Scenario: Management - breast abscess"}]},{"id":"d2222456-9dbf-5408-9e2a-d06f803d315e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"02c4d465-606a-5a45-bb76-7884e6655d29","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"35a080bd-68dc-5e30-8e45-c15b80ad6691","slug":"erythromycin-claithromycin","fullItemName":"Erythromycin and claithromycin"},{"id":"3354cafa-cf61-54b5-8be9-14286cac7d43","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"6882319d-cec4-58ac-a5fb-bfad5a8c44b5","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"5ca61020-4e7e-58c8-89de-963d0f9fad55","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cdcf64dc-7d30-54dc-a4b3-c2cbb2e11318","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9ed2bf1e-0ab0-5318-ab26-7125ea334bc2","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a07ffae7-9042-5683-b005-a39cb64cfe07","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3647fb21-13e1-5087-8638-500053de452d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d3f0e67e-27f7-5dab-bf77-6fd2fb6c04aa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c1eba960-eb26-5c75-a69c-d1b75d6bb18b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e3453acf-65bd-5b33-854f-a6e08be6d75c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d2222456-9dbf-5408-9e2a-d06f803d315e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"5f958044-8323-5dcf-bdde-7e0222a78a19","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8e067517-da50-4625-8b0b-a78200c5c8c9 --><h3>Contraindications and cautions</h3><!-- end field 8e067517-da50-4625-8b0b-a78200c5c8c9 -->","summary":"","htmlStringContent":"<!-- begin item f1a78c0a-b33a-41ac-b128-a78200c5c6e6 --><!-- begin field 45245f08-f00b-4bf5-b67d-a78200c5c8c9 --><ul><li><strong>Do not prescribe flucloxacillin to people with a history of:</strong><ul><li>A <em>true</em> penicillin hypersensitivity. Gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do <em>not</em> constitute an allergy to penicillin.</li><li>Hypersensitivity to cephalosporins.</li><li>Penicillin-associated hepatic dysfunction.</li></ul></li><li><strong>Prescribe flucloxacillin with caution to people with:</strong><br><ul><li>Hepatic impairment.</li><li>Renal impairment — consider dose reduction or a reduction in dosing interval of flucloxacillin in severe renal failure due to the risk of neurotoxicity.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field 45245f08-f00b-4bf5-b67d-a78200c5c8c9 --><!-- end item f1a78c0a-b33a-41ac-b128-a78200c5c6e6 -->","subChapters":[]},{"id":"719027e6-fdc7-5ae4-a85c-cd5fef81e13b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 66f09584-89bc-4a4c-9dac-a78200c5f1f8 --><h3>Adverse effects</h3><!-- end field 66f09584-89bc-4a4c-9dac-a78200c5f1f8 -->","summary":"","htmlStringContent":"<!-- begin item 10cba1b4-9a70-4f70-bf7d-a78200c5ef8d --><!-- begin field a3d1f9fe-c835-4a45-915c-a78200c5f1f8 --><ul><li><strong>Nausea, vomiting, skin rash, and diarrhoea</strong> are the most common adverse effects of flucloxacillin.<ul><li>Consider pseudomembranous colitis if a person develops severe diarrhoea during or after treatment with flucloxacillin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis (delayed or immediate)</strong> is a serious but rare adverse effect of flucloxacillin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.</li><li><strong>Hepatitis and cholestatic jaundice </strong>may occur very rarely after treatment with flucloxacillin. These reactions are related neither to the dose nor to the route of administration of flucloxacillin, and the onset may be delayed for several weeks (up to 2 months) after treatment has stopped. Risk factors include treatment for more than 2 weeks and increasing age.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field a3d1f9fe-c835-4a45-915c-a78200c5f1f8 --><!-- end item 10cba1b4-9a70-4f70-bf7d-a78200c5ef8d -->","subChapters":[]},{"id":"b9ef5f63-f66d-5e51-baae-1ead3a146ec8","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 31020eda-7d5f-446d-893b-a78200c6097c --><h3>Drug interactions</h3><!-- end field 31020eda-7d5f-446d-893b-a78200c6097c -->","summary":"","htmlStringContent":"<!-- begin item feae902a-4fbe-436e-8eda-a78200c60806 --><!-- begin field e228c0aa-595c-42e5-82f7-a78200c6097c --><ul><li><strong>Key drug interactions with flucloxacillin include: </strong><ul><li><strong>Anticoagulants (for example warfarin) </strong>— prolongation of prothrombin time has been reported in people taking penicillins and warfarin concurrently.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of penicillin. Adjustment of the anticoagulant dose may be necessary.</li></ul></li><li><strong>Methotrexate </strong>— penicillins may reduce the excretion of methotrexate. The interaction is not usually serious and risk factors are unknown (even people on low doses of methotrexate have been affected).<ul><li>Monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li><li><strong>Paracetamol</strong> — concurrent administration has been associated with high anion gap metabolic acidosis, especially in people with risk factors.</li></ul></li><li><strong>Oral hormonal contraception </strong>— additional contraceptive precautions are <em>not</em> required during or after courses of penicillins.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">FSRH, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">Preston, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field e228c0aa-595c-42e5-82f7-a78200c6097c --><!-- end item feae902a-4fbe-436e-8eda-a78200c60806 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}